Suppr超能文献

通过靶向CDKN1C抑制MiR-199a-5p可降低常染色体显性多囊肾病中的细胞增殖。

Inhibition of MiR-199a-5p reduced cell proliferation in autosomal dominant polycystic kidney disease through targeting CDKN1C.

作者信息

Sun Lijun, Zhu Jiaqi, Wu Ming, Sun Haipeng, Zhou Chenchen, Fu Lili, Xu Chenggang, Mei Changlin

机构信息

Division of Nephrology, Nephrology Institute of CPLA, Changzheng Hospital, Second Military Medical University, Shanghai, China (mainland).

出版信息

Med Sci Monit. 2015 Jan 15;21:195-200. doi: 10.12659/MSM.892141.

Abstract

BACKGROUND

With a prevalence of about 1:500 to 1:1,000, autosomal dominant polycystic kidney disease (ADPKD) often causes renal failure, with many serious complications. However, there is no Food and Drug Administration (FDA) approved therapy available.

MATERIAL/METHODS: MiR-199a-5p level in ADPKD patient samples, rat model, and cell lines were determined with Realtime PCR assay. After miR-199a-5p inhibitor was transfected, we detected the cell proliferation and apoptosis using an MTT assay and an Annexin V-FITC staining kit, respectively. Finally, TargetScan version 5.1 was used to predict the miRNA target and the target gene of miR-199a-5p was proved by a Luciferase assay.

RESULTS

We identified a dramatically up-regulated microRNA, miR-199a-5p, in ADPKD tissues and cell lines. Our data show that inhibition of miR-199a-5p suppressed cyst cells proliferation and induced cell apoptosis. We found that miR-199a-5p might exert this effect through targeting CDKN1C/p57.

CONCLUSIONS

Up-regulation of miR-199a-5p in ADPKD tissues might promote cell proliferation through suppressing CDKN1C, suggesting miR-199a-5p as a novel target for ADPKD treatment.

摘要

背景

常染色体显性多囊肾病(ADPKD)的患病率约为1:500至1:1000,常导致肾衰竭,并伴有许多严重并发症。然而,目前尚无美国食品药品监督管理局(FDA)批准的治疗方法。

材料/方法:采用实时定量PCR检测ADPKD患者样本、大鼠模型和细胞系中miR-199a-5p的水平。转染miR-199a-5p抑制剂后,分别使用MTT法和Annexin V-FITC染色试剂盒检测细胞增殖和凋亡情况。最后,使用TargetScan 5.1版本预测miRNA靶点,并通过荧光素酶报告基因检测法验证miR-199a-5p的靶基因。

结果

我们在ADPKD组织和细胞系中鉴定出一种显著上调的微小RNA,即miR-199a-5p。我们的数据表明,抑制miR-199a-5p可抑制囊肿细胞增殖并诱导细胞凋亡。我们发现miR-199a-5p可能通过靶向CDKN1C/p57发挥这种作用。

结论

ADPKD组织中miR-199a-5p的上调可能通过抑制CDKN1C促进细胞增殖,提示miR-199a-5p可作为ADPKD治疗的新靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/882c/4304454/f1f26898f486/medscimonit-21-195-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验